Business Context and Reporting Period
This Form 8-K Current Report was filed by Tvardi Therapeutics, Inc. on July 8, 2025. The report discloses a corporate governance event involving the departure of a Board member. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol TVRD.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a specific corporate event.
Material Changes
The material change reported is the resignation of Shaheen Wirk as a member of the Board of Directors, effective July 8, 2025. Dr. Wirk had served on the Board since March 2024 and previously acted as a special advisor. The Company explicitly states that the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of new risks and contingencies. Management commentary is limited to expressing gratitude for Dr. Wirk's contributions to the Company.
Key Facts for Investor Verification
- Event: Resignation of Director Shaheen Wirk.
- Date: July 8, 2025.
- Reason: No disagreement with the Company; voluntary departure.
- Service History: Board member since March 2024; former special advisor.
- Financial Impact: No financial data or impact disclosed in this filing.